SEC Tracker
Get the app
FDMT · XBRL financial data

4D Molecular Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (FDMT's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue20,204(19)*28531*1415—year only3,0473,781
Revenue from contracts with customers20,204(19)*28531*141590year only3,0473,781
General and administrative9,11210,605*10,29410,60112,65113,031*12,93611,52011,83712,767*11,68712,524
Total operating expenses34,17836,633*38,16442,46151,13556,118*53,63559,47161,27570,375*76,66780,806
Operating income (loss)(13,974)(36,652)*(38,136)(42,456)(51,132)(56,117)*(53,621)(59,456)(61,185)14,715*(73,620)(77,025)
Interest income3,8764,380*5,7457,5487,2906,467*5,5824,8594,3304,704*4,8644,255
Other income (expense)(158)(11)*(10)(45)(1)(21)*67(61)(21)(22)*(4)(166)
Income tax expense (benefit)00*0000*0000*00
Net income (loss)(10,256)(32,283)*(32,401)(34,953)(43,843)(49,671)*(47,972)(54,658)(56,876)19,397*(68,760)(72,936)
Earnings per share, basic USD per share(0.24)(0.75)*(0.66)(0.63)(0.79)(0.89)*(0.86)(0.98)(1.01)—(1.01)(1.04)
Earnings per share, diluted USD per share(0.24)(0.75)*(0.66)(0.63)(0.79)(0.89)*(0.86)(0.98)(1.01)—(1.01)(1.04)
Weighted average shares, basic thousands of shares42,25743,057*49,27255,28355,55455,630*55,74455,92756,12663,854*68,06570,272
Weighted average shares, diluted thousands of shares42,25743,057*49,27255,28355,55455,630*55,74455,92756,12663,854*68,06570,272

Balance sheet

CSV

Fiscal quarters (FDMT's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents275,678249,108275,594189,061187,539149,336133,52677,15948,55560,24172,48870,372
Marketable securities43,98639,124250,317352,885314,353275,541187,911216,066256,508342,414318,404290,962
Marketable securities, non-current010,95462,94235,71548,77980,583137,004123,80667,165111,37966,73969,295
Prepaid and other current assets8,5798,3569,67810,6878,86510,05511,12910,0627,31410,47914,47217,012
Total current assets328,243296,588535,589552,633510,757434,932332,566303,287312,377413,134405,364382,957
Property and equipment, net20,73820,12619,46418,76119,86619,53418,74517,50516,15314,86713,58712,379
Right-of-use asset11,95011,53911,11810,68821,76221,07420,37119,64918,90718,14317,35716,548
Total assets361,613339,891629,884620,117604,028560,384515,729473,637423,982566,711512,905492,615
Accounts payable4,7133,5154,2173,4312,9244,3864,1518,7006,86311,15914,69212,522
Accrued liabilities10,19412,0149,01312,77621,41518,86916,20319,19024,18926,87422,86625,431
Total current liabilities18,16318,95116,40319,40329,46529,14926,89934,67737,10743,98543,40447,673
Long-term debt—————————0—19,587
Lease liability, non-current12,03111,52210,99810,46019,74318,96918,17417,35616,56815,82115,04914,256
Total liabilities31,67932,06229,32331,77751,08049,77846,00652,74754,99961,04761,06984,956
Accumulated deficit(383,044)(415,327)(447,728)(482,681)(526,524)(576,195)(624,167)(678,825)(735,701)(716,304)(785,064)(858,000)
Total stockholders' equity329,934307,829600,561588,340552,948510,606469,723420,890368,983505,664451,836407,659
Total liabilities and equity361,613339,891629,884620,117604,028560,384515,729473,637423,982566,711512,905492,615
Common shares outstanding (cover page) thousands of shares42,75449,77851,15751,91451,99745,79446,32546,70046,77157,60852,27255,214

Cash flows

CSV

Fiscal quarters (FDMT's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(10,256)(32,283)*(32,401)(34,953)(43,843)(49,671)*(47,972)(54,658)(56,876)19,397*(68,760)(72,936)
Stock-based compensation4,562*5,913*5,9746,074*6,490*7,578*6,9864,958*4,519*5,553*4,4535,884*
Net cash from operating activities(1,171)*(24,650)*(29,088)(30,243)*(29,391)*(45,863)*(47,758)(43,377)*(46,498)*28,551*(68,125)(69,999)*
Purchases of property and equipment405*549*710349*1,778*949*63166*(91)*(70)*——
Net cash from investing activities29,981*(6,682)*(263,258)(73,539)*27,301*7,059*31,948(13,852)*17,778*(128,847)*68,88825,544*
Net cash from financing activities10,557*4,762*318,83217,249*568*601*0862*116*111,982*11,48442,339*
Net change in cash39,367*(26,570)*26,486(86,533)*(1,522)*(38,203)*(15,810)(56,367)*(28,604)*11,686*12,247(2,116)*

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
4D Molecular Therapeutics70,3723,781(69,999)*55.2M5.2 quarters 10-QJun 30, 2026
XOMA Royalty85,60012,3186,12112.5M— 10-QMar 31, 2026
Lexicon Pharmaceuticals40,924692(9,192)*445.0M20.7 quarters 10-QJun 30, 2026
Lineage Cell Therapeutics37,3551,069(7,244)*252.9M7.0 quarters 10-QJun 30, 2026
Omeros1,98828,5294,149*72.4M— 10-QJun 30, 2026
Forte Biosciences49,629not reported(22,702)*21.2M8.7 quarters 10-QJun 30, 2026
Crescent Biopharma171,5930(19,463)*37.1M8.8 quarters 10-QJun 30, 2026
Monopar Therapeutics52,7580*(3,247)*6.7M32.4 quarters 10-QJun 30, 2026
Sangamo Therapeutics27,5861,442(19,282)414.3M1.4 quarters 10-QMar 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.